Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
SUMMARY Background: Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid precursor protein gene, virtually all adults with Down syndrome (DS) develop Alzheimer disease (AD) pathology by age 40 and are at high risk for dementia given their increased life expectancy. Comparison of cerebrospinal fluid (CSF) biomarker patterns in DS with those of autosomal dominant AD (ADAD) mutation carriers (MC) will enhance our understanding of disease mechanisms in these two genetically high risk groups. Methods: CSF samples obtained from adults with DS (n=41) and similarly-aged ADAD MC (n=192) and non-carrier (NC, n=108) siblings (aged 30–61 years) were analyzed for markers of amyloid-β (Aβ40, Aβ42), phosphorylated tau-related processes (pTau181), neuronal/axonal/synaptic injury (total tau, visinin-like protein 1 [VILIP-1], neurofilament light chain [NfL], synaptosomal-associated protein 25 [SNAP-25]), and astrogliosis/neuroinflammation (chitinase-3-like protein 1 [YKL-40]) via immunoassay. Biomarker concentrations were compared as a function of dementia status (asymptomatic/symptomatic), and linear regression was used to evaluate and compare the relationship between biomarker levels and age among groups. Findings: Adults with DS exhibited patterns of AD-related CSF biomarkers remarkably similar to ADAD MC, including reductions in the Aβ42/Aβ40 ratio and increases in markers of phosphorylated tau-related processes, neuronal/axonal/synaptic injury, and astrogliosis/neuroinflammation, with greater degrees of abnormality in individuals with dementia. Differences included overall higher levels of Aβ and YKL-40 in DS and potential elevations in CSF tau and NfL in the asymptomatic (non-demented) stage. Interpretation: CSF biomarker profiles are useful for identifying and tracking AD-related processes in DS and, as such, will likely have utility in clinical trial design in this understudied at-risk population. Funding: National Institute on Aging (U01-AG051406, U01-AG051412, UF1-AG032438), Eunice Kennedy Shriver National Institute of Child Health and Human Development, German Center for Neurodegenerative Diseases, and Research and Development Grants for Dementia from Japan Agency for Medical Research and Development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734
Self-citationMattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citationSymptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502
Self-citation
Cited by
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
Janelidze, S., Christian, B. T., Price, J., Laymon, C., Schupf, N., Klunk, W. E., Lott, I., Silverman, W., Rosas, H. D., Zaman, S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1740 · Cited by 60
Self-citationSturchio, A., (DIAN), T. D. I. A. C., Dwivedi, A. K., Malm, T., Wood, M. J. A., Cilia, R., Sharma, J. S., Hill, E. J., Schneider, L. S., Graff-Radford, N. R., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220808 · Cited by 57
Self-citationBoerwinkle, A. H., Gordon, B. A., Wisch, J., Flores, S., Henson, R. L., Butt, O. H., McKay, N., Chen, C. D., Benzinger, T. L. S., Fagan, A. M., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00408-2 · Cited by 55
Self-citationRodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches
Farrell, C., Mumford, P., & Wiseman, F. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.909669 · Cited by 22
Metadata
- Authors
- Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E., Christian, B. T., Lai, F., Rosas, H. D., Schupf, N., Krinsky-McHale, S., Silverman, W., Lee, J. H., Klunk, W. E., Handen, B. L., Allegri, R. F., Chhatwal, J. P., Day, G. S., Graff-Radford, N. R., Jucker, M., Levin, J., Martins, R. N., Masters, C. L., Mori, H., Mummery, C. J., Niimi, Y., Ringman, J. M., Salloway, S., Schofield, P. R., Shoji, M., & Lott, I. T.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 20
- Issue
- 8
- Pages
- 615-626
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W3184028641
- Cited by
- 70
- References
- 20
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. https://app.cochat.ai/papers/10.1016/s1474-4422(21)00139-3
- The paper
- Fagan, A. M., Henson, R. L., Li, Y., Boerwinkle, A. H., Xiong, C., Bateman, R. J., Goate, A., Ances, B. M., Doran, E., Christian, B. T., Lai, F., Rosas, H. D., Schupf, N., Krinsky-McHale, S., Silverman, W., Lee, J. H., Klunk, W. E., Handen, B. L., Allegri, R. F., . . . Lott, I. T. (2021). Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(21)00139-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.